kotturi
f
et
al
naiv
precursor
frequenc
mhc
bind
rather
degre
epitop
divers
shape
cell
immunodomin
abstract
plasmacytoid
dendrit
cell
pdc
first
describ
interferonproduc
cell
mani
year
overlap
characterist
lymphocyt
classic
dendrit
cell
cdc
creat
confus
exact
ontogeni
viewpoint
articl
natur
review
immunolog
ask
five
leader
field
discuss
thought
develop
function
pdc
cell
serv
mainli
major
sourc
type
interferon
also
make
import
contribut
immun
respons
close
relat
plasmacytoid
dendrit
cell
pdc
classic
dendrit
cell
cdc
subset
name
pdc
misnom
bori
reizi
point
soum
liu
plasmacytoid
dendrit
inde
misnom
strict
sens
refer
two
mutual
exclus
cell
morpholog
howev
think
name
appropri
gener
sens
reflect
uniqu
dual
natur
cell
type
inde
pdc
share
key
featur
cdc
includ
common
progenitor
depend
cytokin
fmsrelat
tyrosin
kinas
ligand
constitut
express
receptor
relat
global
gene
express
profil
suprem
pathogensens
capac
moreov
distinct
cdc
subset
close
relat
pdc
describ
recent
hand
plasmacytoid
refer
nondendrit
morpholog
secretori
lymphocyt
believ
pdc
start
along
common
dc
development
pathway
get
divert
lymphocytelik
plasmacytoid
state
distinct
signal
pdcspecif
transcript
factor
also
known
state
fit
secretori
function
pdc
revers
toward
default
cdc
state
exampl
follow
activ
vitro
inde
recent
shown
delet
gene
encod
matur
pdc
caus
spontan
convers
cdclike
cell
suggest
pdc
one
gene
away
cdc
cell
fate
colonna
pdc
cdc
close
relat
development
studi
shown
pdc
cdc
deriv
common
dc
progenitor
share
key
transcript
factor
interferonregulatori
factor
moreov
pdc
like
monocytederiv
inflammatori
dc
enter
cell
area
lymphoid
organ
directli
blood
high
endotheli
venul
phenotyp
pdc
cdc
lack
lymphocyt
lineag
marker
express
mhc
class
ii
molecul
mice
human
express
follow
activ
pdc
cdc
upregul
mhc
class
ii
express
acquir
enhanc
cell
stimulatori
capac
thu
pdc
consid
subset
dc
name
pdc
ration
practic
howev
name
perfect
mainli
pdc
profession
antigenpres
cell
apc
fact
quit
poor
prime
naiv
cell
thu
name
pdc
reflect
development
rather
function
connect
cdc
giorgio
trinchieri
studi
dc
ontogeni
greatli
progress
shown
cell
cdc
trait
may
origin
differ
progenitor
converg
differenti
give
rise
cell
similar
special
function
gene
express
pdc
distinct
cdc
unless
activ
spheric
morpholog
without
dendrit
pdc
share
characterist
secretori
cell
especi
antibodysecret
plasma
cell
pattern
gene
express
includ
partial
rearrang
immuno
globulin
gene
closer
b
cell
myeloid
cell
howev
viral
infect
pdc
differenti
cell
function
gene
express
characterist
cdc
even
absenc
identifi
pdc
interferonproduc
cell
ipc
morpholog
character
pathologist
plasmacytoid
cell
monocyt
pdc
terminolog
introduc
publish
ipc
human
peripher
blood
dc
base
morpholog
antigenpres
function
howev
although
term
pdc
may
misnom
use
focus
attent
cell
type
retain
without
impli
refer
morpholog
function
cell
type
franck
barrat
first
need
defin
mean
term
pdc
inde
cell
call
pdc
whether
exist
ipc
differenti
dc
quit
differ
morpholog
function
confus
come
abil
pdc
mediat
innat
immun
respons
regul
adapt
immun
ipc
produc
larg
amount
type
type
iii
interferon
ifn
lymphoid
shape
plasma
cell
morpholog
pattern
cell
surfac
marker
includ
lymphoid
marker
suggest
differ
ontogeni
cdc
addit
ipc
low
express
level
costimulatori
molecul
poor
cell
prime
capabl
pdc
littl
common
cdc
howev
follow
activ
pdc
rapidli
reorgan
morpholog
resembl
cdc
presenc
dendrit
high
express
level
costimulatori
molecul
complet
shift
cytokin
product
profil
nonetheless
even
full
differenti
occur
still
major
differ
pdc
cdc
includ
distinct
pattern
migrat
pdc
origin
bone
marrow
move
blood
follow
activ
migrat
cell
area
secondari
lymphoid
organ
inflam
tissu
final
import
note
mous
human
pdc
gener
differ
qualit
respons
particular
follow
tolllik
receptor
tlr
signal
exampl
activ
mous
pdc
secret
larg
amount
rel
low
level
type
type
iii
ifn
variat
creat
confus
role
function
cell
vivo
michel
gilliet
strike
differ
morpholog
gene
express
function
capac
origin
suggest
possibl
pdc
cdc
belong
distinct
development
lineag
concept
challeng
howev
find
pdc
cdc
aris
common
progenitor
develop
subset
requir
recent
identif
essenti
specif
transcript
regul
pdc
develop
provid
undisput
evid
pdc
develop
along
distinct
pathway
howev
identif
also
reinforc
concept
pdc
cdc
close
relat
pdc
appear
spontan
convert
cdclike
cell
mice
regard
whether
pdc
misnom
rest
pdc
plasma
celllik
plasmacytoid
morpholog
appear
round
cell
excentr
nucleu
without
dendrit
stage
pdc
unabl
prime
naiv
cell
activ
produc
larg
amount
type
ifn
follow
activ
pdc
lose
plasmacytoid
morpholog
abil
produc
type
ifn
differenti
cell
dendrit
morpholog
capac
prime
naiv
cell
thu
plasmacytoid
dendrit
state
cell
morpholog
function
distinct
indic
term
pdc
fact
misnom
term
plasmacytoid
dendrit
cell
precursor
plasmacytoidderiv
dendrit
cell
would
appropri
pdc
activ
strictli
depend
cell
activ
way
gt
major
innat
receptor
activ
pdc
preferenti
use
two
tlr
repres
similar
pdc
rest
b
cell
recogn
rna
dna
virus
respect
well
nucleic
acid
releas
die
cell
patholog
condit
nucleic
acid
often
associ
cation
protein
chaperon
bound
immunoglobulin
immun
complex
interact
membran
fc
receptor
fcr
pdc
particip
innat
resist
viral
bacteri
infect
promot
tissu
repair
follow
injuri
also
mediat
immunopatholog
skin
mucos
surfac
pdc
probabl
role
homeostat
interact
commens
flora
howev
receptor
clearli
involv
regul
pdc
includ
sialic
acidbind
immunoglobulinlik
lectin
h
siglech
blood
dc
antigen
also
known
neg
affect
ifn
product
tlr
convers
mannaninhibit
lectin
enhanc
virusinduc
ifn
product
fcr
lectin
dc
natur
killer
lectin
group
receptor
also
known
involv
nucleic
acid
antigen
uptak
pdc
surprisingli
cytoplasm
nucleic
acid
sensor
upregul
ifn
product
cell
type
member
retino
acidinduc
gene
rigi
famili
may
less
import
pdc
clear
select
express
pdc
central
abil
produc
type
ifn
respons
rna
dna
virus
complex
howev
evid
pdc
also
sens
dna
via
myeloid
differenti
primari
respons
protein
depend
dna
sensor
kim
et
al
identifi
natur
receptor
cytosol
dexdhbox
helicas
human
pdc
also
activ
granulocytemacrophag
colonystimul
factor
gmcsf
cytokin
activ
pdc
differenti
matur
dc
abil
stimul
naiv
cell
longer
produc
type
ifn
vitro
studi
yield
interest
data
gmcsf
activ
pdc
drive
helper
h
h
cell
respons
respect
howev
physiolog
relev
pdc
activ
pathway
still
remain
unclear
vivo
counterpart
gmcsfactiv
pdc
yet
identifi
given
multitud
pathogensens
pathway
cell
type
think
unlik
pdc
would
singlemind
even
within
tlr
famili
addit
receptor
express
pdc
murin
furthermor
mention
mg
member
protein
famili
helicas
implic
dna
sens
pdc
usual
help
insight
provid
genet
casanova
colleagu
describ
human
patient
defici
prevent
signal
surprisingli
patient
predispos
viral
infect
impli
either
pdc
larg
dispens
contemporari
human
lifestyl
like
altern
pathway
pdc
activ
exist
independ
pdc
activ
strictli
depend
nucleic
acid
recognit
cell
activ
signal
nontlr
receptor
receptor
ifn
receptor
differ
consequ
uniqu
nucleic
acid
recognit
pdc
natur
respons
induc
quickli
produc
astronom
amount
type
ifn
case
stimuli
promot
differenti
pdc
matur
dc
induc
initi
burst
ifn
product
suggest
abil
pdc
contribut
innat
immun
respons
infect
produc
ifn
restrict
nucleic
acid
recognit
recognit
nucleic
acid
endosom
well
describ
clear
domin
pathway
howev
signal
molecul
recent
describ
cytosol
helicas
appear
particip
nucleic
acid
respons
well
mc
pdc
express
type
ifn
receptor
type
ifn
stimul
pdc
either
autocrin
paracrin
manner
promot
activ
migrat
augment
type
ifn
secret
pdc
also
activ
member
tumour
necrosi
factor
tnf
tnf
receptor
tnfr
superfamili
includ
ligand
pdct
cell
crosstalk
result
pdcmediat
secret
type
ifn
well
cell
polar
toward
h
h
cell
phenotyp
extend
feedback
loop
pdc
influenc
cytokin
secret
cell
instanc
cellderiv
stimul
human
pdc
receptor
induc
pdc
surviv
final
pdc
express
pattern
recognit
receptor
prr
addit
human
rigilik
receptor
rlr
recogn
lipopeptid
wherea
rlr
cytosol
helicas
detect
viral
rna
howev
clear
prr
contribut
pdc
activ
express
function
prr
particular
dna
sensor
nodlik
receptor
nlr
remain
investig
fb
first
human
black
box
clear
data
describ
role
pdc
cell
respons
question
hard
address
technic
base
vitro
work
know
antigen
uptak
pdc
quit
differ
seen
cdc
even
pdc
fulli
differenti
pdc
express
high
level
mhc
class
ii
molecul
activ
cell
mixedleukocyt
reaction
assay
current
think
pdc
may
effect
present
viral
antigen
memori
cell
addit
data
mice
role
pdc
specif
organ
lung
suggest
pdc
activ
particip
primari
cell
respons
respect
cell
differenti
rememb
mice
pdc
secret
along
ifn
key
cytokin
promot
h
cell
differenti
human
pdc
produc
littl
although
larg
amount
ifn
produc
like
promot
h
cell
differenti
well
sever
studi
shown
pdc
effici
present
endogen
antigen
poorli
present
exogen
antigen
compar
cdc
one
reason
pdc
unabl
take
exogen
antigen
phagocytosi
macropinocytosi
anoth
factor
prevent
pdc
present
exogen
antigen
effici
cdc
pdc
accumul
longliv
peptidemhc
class
ii
complex
cell
surfac
due
inabl
activ
pdc
silenc
mhc
class
ii
transactiv
ciita
therefor
synthesi
new
mhc
class
ii
molecul
maintain
even
matur
furthermor
activ
pdc
downregul
ubiquityl
mhc
class
ii
molecul
molecul
continu
turn
whether
pdc
crosspres
exogen
antigen
remain
controversi
number
studi
demonstr
mous
pdc
possess
capac
crosspresent
howev
recent
vitro
studi
report
human
pdc
crosspres
viral
antigen
load
directli
onto
mhc
class
molecul
earli
recycl
endosom
vesicl
need
transport
cytoplasm
implic
find
expans
differenti
virusspecif
cell
popul
current
unclear
gt
sinc
identif
pdc
antigen
present
abil
observ
much
lower
cdc
caus
concern
contamin
pdc
popul
even
less
cdc
could
account
abil
pdc
stimul
cell
also
abil
pdc
take
antigen
phagocyt
activ
remain
controversi
issu
free
antigen
antigen
complex
immunoglobulin
intern
pdc
via
fcr
lectin
receptor
crosspresent
antigen
report
also
mention
mg
mhc
class
ii
express
differenti
regul
pdc
cdc
well
account
poor
peptideload
present
abil
pdc
allow
activ
pdc
present
viral
antigen
even
infect
addit
pdc
interact
cell
natur
killer
nk
cell
part
cell
membran
receptor
interact
lead
reciproc
activ
pdc
modul
cell
activ
often
exclus
toward
regulatori
cell
phenotyp
moreov
pdcderiv
ifn
regul
cell
directli
indirectli
modul
apc
function
mc
pdc
ineffici
prime
naiv
cell
henc
unlik
elicit
primari
cell
respons
given
perhap
surpris
antigen
process
present
machineri
pdc
quit
differ
cdc
like
mhc
class
iiexpress
cell
howev
pdc
promot
expans
memori
cell
popul
therebi
facilit
secondari
immun
respons
pdc
also
contribut
prime
antigenspecif
cell
promot
surviv
pdc
implic
differenti
almost
everi
type
cell
includ
h
h
h
h
regulatori
reg
cell
specul
result
may
reflect
plastic
pdc
might
induc
differ
cell
type
depend
anatom
locat
cytokin
microenviron
immers
activ
state
hypothesi
support
vitro
studi
vivo
studi
pdcdeplet
antibodi
howev
avail
pdcdeplet
antibodi
crossreact
may
deplet
addit
cell
type
import
valid
pdc
plastic
vivo
altern
approach
exampl
use
transgen
mice
pdc
induc
select
deplet
inject
diphtheria
toxin
larg
bodi
evid
suggest
pdc
effici
present
antigen
steadi
state
consist
low
level
mhc
class
ii
express
nondendrit
morpholog
activ
tlr
ligand
pdc
shown
acquir
capac
antigen
present
crosspresent
certain
model
two
key
unresolv
issu
remain
first
import
antigen
present
pdc
cours
natur
infect
especi
presenc
cdc
primari
present
second
activ
pdc
maintain
cell
fate
differenti
activ
cdc
latter
case
would
perfectli
entitl
prime
cell
differenti
well
document
vitro
remain
conclus
demonstr
infect
model
vivo
pdc
report
promot
proinflammatori
tolerogen
immun
respons
abl
show
dual
function
fb
differ
apc
type
dual
function
well
accept
cdc
depend
cell
activ
microenviron
occur
unexpect
though
pdc
tolerogen
activ
tlr
bori
reizi
complet
phd
immunolog
irun
r
cohen
weizmann
institut
scienc
rehovot
israel
carri
postdoctor
train
philip
leder
harvard
medic
school
boston
massachusett
usa
current
associ
professor
depart
microbiolog
immunolog
columbia
univers
new
york
usa
lab
broadli
interest
regul
haematopoiesi
stem
cell
function
dendrit
cell
develop
homeostasi
giorgio
trinchieri
direct
cancer
inflamm
program
nation
cancer
institut
frederick
maryland
usa
sinc
train
medicin
univers
turin
itali
basel
institut
immunolog
switzerland
group
wistar
institut
philadelphia
pennsylvania
usa
discov
interest
interplay
inflamm
innat
resist
adapt
immun
role
proinflammatori
cytokin
regul
haematopoiesi
innat
resist
immun
involv
earli
discoveri
character
plasmacytoid
dendrit
cell
human
mous
recent
work
focus
role
inflamm
cancer
role
microbiota
local
system
regul
inflamm
gt
agre
respect
pdc
unlik
cdc
depend
state
matur
exist
differ
subset
may
mediat
immunostimulatori
regulatori
function
proinflammatori
abil
pdc
larg
depend
ifn
product
also
immunostimulatori
product
cytokin
cellular
interact
classic
activ
ligand
pdc
produc
type
ifn
cytokin
implic
h
h
cell
differenti
addit
pdc
secret
chemokin
contribut
inflamm
includ
ccchemokin
ligand
cxcchemokin
ligand
clinic
studi
strongli
support
proinflammatori
function
pdc
autoimmun
diseas
particularli
system
lupu
erythematosu
sle
psoriasi
conclus
corrobor
result
mous
model
auto
immun
prompt
develop
therapeut
strategi
deplet
block
pdc
prevent
treat
autoimmun
howev
also
evid
tolerogen
pdc
present
human
tumour
includ
melanoma
breast
ovarian
cancer
although
immunosuppress
tumour
micro
environ
may
facilit
recruit
induct
tolerogen
pdc
activ
tumourassoci
pdc
ligand
promot
tumour
reject
gt
immunoregulatori
abil
pdc
base
differ
mechan
includ
suboptim
antigen
present
express
indoleamin
ido
delet
activ
cell
induct
reg
cell
mani
publish
studi
suggest
opposit
function
could
mediat
differ
subset
stage
differenti
pdc
marker
ccchemokin
receptor
use
character
pdc
differ
stimulatori
regulatori
function
remain
unclear
whether
regulatori
function
properti
immatur
pdc
matur
andor
activ
pdc
although
product
ifn
pdc
regulatori
function
often
propos
dissoci
ifn
involv
activ
reg
cell
inhibit
reg
cell
differenti
nonactiv
state
pdc
appear
special
peripher
toler
inde
nonactiv
human
pdc
found
express
high
level
ico
ligand
icosl
promot
surviv
expans
product
subset
forkhead
box
reg
cell
express
induc
cell
costimul
ico
mous
studi
shown
nonactiv
pdc
suppress
inflammatori
respons
inhal
allergen
promot
allogen
stem
cell
engraft
inhibit
acut
graftversushost
diseas
mediat
toler
solid
graft
induc
reg
cell
pdc
also
mediat
oral
toler
antigen
feed
induc
anergi
delet
antigenspecif
cell
liver
viral
infect
pdc
activ
produc
larg
amount
type
ifn
appear
central
earli
induct
protect
antivir
immun
respons
activ
nk
cell
b
cell
cell
cdc
particular
abil
pdcderiv
type
ifn
activ
cdc
appear
crucial
induct
cellmedi
immun
context
viral
infect
activ
pdc
may
also
differenti
matur
dc
stimul
cell
howev
contrast
cdc
matur
human
pdc
maintain
high
level
icosl
express
retain
abil
induc
reg
cell
find
indic
pdc
might
intrins
capac
drive
peripher
toler
even
matur
differenti
stage
may
contribut
contract
effector
phase
cell
respons
prevent
excess
inflamm
support
hypothesi
pdc
deplet
viral
infect
found
exacerb
immunopatholog
host
worth
note
littl
evid
role
pdc
toler
vivo
sever
studi
made
claim
limit
poor
phenotyp
definit
pdc
andor
artifici
manipul
expans
pdc
popul
use
tumour
found
mice
constitut
lack
pdc
live
ripe
old
age
without
obviou
sign
autoimmun
inflamm
suggest
pdc
mediat
domin
toler
way
reg
cell
cours
exclud
import
role
pdc
promot
toler
certain
circumst
establish
oral
toler
eleg
recent
studi
show
abolish
antigen
present
pdc
increas
auto
immun
inflamm
brain
howev
net
effect
pdc
model
still
remain
establish
given
pdc
poor
antigen
present
absenc
activ
product
activ
type
ifn
potent
adjuv
appear
like
pdc
would
facilit
protect
immun
rather
toler
pdc
seem
mainli
contribut
immun
function
produc
type
ifn
howev
leukocyt
nonimmun
cell
also
produc
type
ifnswhi
think
need
cell
dedic
type
respons
mg
two
characterist
distinguish
type
ifn
product
pdc
cell
first
speed
express
second
magnitud
express
pdc
abl
produc
rapidli
owe
constitut
high
express
level
allow
rapid
assembl
multiprotein
signal
transduct
complex
induc
ifn
cell
express
constitut
requir
upregul
respons
feedback
signal
follow
activ
extraordinari
abil
pdc
produc
larg
amount
type
ifn
illustr
fact
found
account
type
ifn
produc
peripher
blood
mononuclear
cell
respons
mani
virus
partli
due
uniqu
abil
pdc
retain
dna
earli
endosom
extend
period
time
allow
sustain
activ
induct
ifn
need
special
cell
dedic
rapid
potent
product
type
ifn
still
unclear
recent
found
follow
skin
injuri
pdc
quickli
infiltr
wound
sens
nucleic
acid
releas
die
cell
rapidli
produc
type
ifn
fast
transient
product
type
ifn
pdc
appear
crucial
promot
inflammatori
respons
tissu
repair
skin
wound
seem
plausibl
wellcontrol
activ
special
cell
type
rapidli
transient
produc
larg
amount
type
ifn
necessari
kickstart
protect
immun
respons
avoid
excess
uncontrol
inflamm
could
result
activ
mani
differ
cell
type
produc
type
ifn
requir
tight
control
type
ifn
product
illustr
fact
chronic
pdc
activ
drive
autoimmun
diseas
psoriasi
sle
br
mg
said
among
uniqu
featur
type
ifn
product
pdc
kinet
type
ligand
recogn
instanc
pdc
sourc
ifn
respons
ligand
cpg
oligonucleotid
despit
widespread
express
furthermor
ifn
induc
almost
immedi
follow
pdc
activ
spectacular
insight
made
recent
molecular
basi
tlr
coupl
ifn
express
pdc
although
overal
mechan
remain
elus
ultrafast
product
ifn
respons
endosom
nucleic
acid
seem
obviou
adapt
resist
invad
virus
detect
control
within
first
hour
infect
avoid
acut
cell
damag
cytopath
virus
rapid
replic
lead
cell
exhaust
noncytopath
virus
best
accomplish
constant
patrol
recircul
cell
equip
uniqu
detect
signal
mechan
moreov
potenti
danger
secret
ifn
halt
rapidli
prevent
steadi
state
inde
receptor
specif
express
pdc
inhibitori
includ
human
immunoglobulinlik
transcript
provid
neg
feedback
ifnreceiv
cell
collect
specif
molecular
pathway
requir
power
ifn
secret
well
tight
control
appear
justifi
dedic
cell
type
recent
studi
mice
suggest
vivo
multipl
cellular
sourc
contribut
host
antivir
respons
mediat
type
ifn
contribut
pdc
limit
magnitud
time
clearli
variou
cell
type
includ
macrophag
inflammatori
monocyt
dc
stromal
cell
crucial
sourc
type
ifn
viral
infect
howev
discuss
pdc
respons
occur
earli
infect
pdc
may
essenti
limit
viral
replic
control
level
sourc
type
ifn
becom
avail
provid
earli
type
ifn
pdc
may
also
promot
express
key
ifninduc
antivir
moleculessuch
rlr
rnaactiv
protein
kinas
pkr
neighbour
cell
final
import
pdc
sourc
type
ifn
vivo
probabl
depend
type
viru
site
infect
clinic
evid
suggest
pdc
may
crucial
control
viral
infect
skin
mice
pdc
provid
import
sourc
type
ifn
viru
gain
access
bloodstream
mucos
site
studi
dispar
viral
infect
pdcdeplet
mice
warrant
fulli
assess
pdc
function
immun
respons
gt
agre
pdc
uniqu
constitut
express
enabl
rapidli
secret
ifn
respons
agonist
remain
unclear
protein
may
produc
rest
pdc
activ
express
ifn
transcript
per
cell
basi
pdc
effect
ifn
produc
cell
type
respons
earli
peak
ifn
product
respons
virus
respons
agonist
howev
cell
haematopoiet
respond
viral
infect
exogen
endogen
stimuli
produc
low
probabl
sustain
level
ifn
induct
ifn
mainli
depend
coupl
tir
domaincontain
adaptor
protein
induc
trif
cyto
plasmic
receptor
helicaselik
receptor
rna
dna
sensor
nucleotidebind
oligomer
domain
protein
nod
peptid
addit
feedback
loop
repres
import
amplifi
mechan
thu
pdc
may
import
rapid
earli
respons
need
acut
infect
redund
mechan
involv
differ
induc
anatom
locat
kinet
respons
take
ensur
full
persist
protect
infect
fb
would
argu
pdc
distinct
cell
two
key
paramet
first
kinet
magnitud
ifn
product
owe
constitut
presenc
high
level
second
fact
pdc
activ
self
nucleic
acid
provid
self
rna
dna
complex
cation
peptid
associ
antibodi
specif
nuclear
compon
well
document
follow
tissu
injuri
autoimmun
set
sle
pdc
effector
cell
found
tissu
migrat
quickli
follow
injuri
thu
among
first
innat
cell
initi
respons
insult
one
therefor
imagin
cell
circul
blood
attract
tissu
follow
injuri
nucleic
acid
complex
cation
peptid
trigger
initi
wave
ifn
product
via
activ
interestingli
recognit
foreign
nucleic
acid
probabl
necessari
initi
burst
ifn
product
although
pdc
like
redund
antivir
respons
provid
one
layer
respons
abil
quickli
produc
ifn
respond
self
foreign
nucleic
acid
make
uniqu
player
immun
system
pdc
like
use
therapeut
target
br
pdc
seem
play
specif
role
immun
process
exampl
involv
respons
certain
virus
coronavirus
contribut
type
autoimmun
inflamm
precis
reason
may
turn
excel
therapeut
target
pdcfocus
approach
would
select
gener
target
ifn
respons
instanc
dampen
pdc
function
might
decreas
patholog
inflamm
patient
sle
psoriasi
without
impair
antivir
defenc
gener
howev
key
prerequisit
better
understand
exact
role
pdc
immun
respons
particularli
autoimmun
anoth
crucial
step
identifi
new
molecular
target
pdc
exampl
pdcspecif
signal
event
coupl
nucleic
acid
sens
ifn
secret
final
pdcderiv
leukaemia
also
known
haematoderm
neoplasm
rare
leukaemia
alway
fatal
present
acut
need
therapi
given
pathogen
role
type
ifn
sle
block
antibodi
specif
type
ifn
receptor
ifnar
current
test
potenti
treatment
howev
global
blockad
type
ifn
may
result
increas
suscept
viral
infect
pdc
identifi
major
sourc
type
ifn
sle
function
blockad
antibodymedi
ablat
pdc
may
provid
attract
altern
block
type
ifn
inhibit
pdc
would
specif
elimin
sourc
excess
type
ifn
promot
autoimmun
preserv
protect
type
ifn
respons
virus
cell
gt
alreadi
mention
pdc
may
direct
patholog
role
sle
psoriasi
least
part
product
ifn
addit
quit
strong
evid
anim
experi
human
pdc
tumour
help
creat
immunosuppress
environ
associ
unfavour
prognosi
also
abil
pdc
induc
immun
toler
might
import
role
prevent
graft
reject
autoimmun
thu
theori
pdc
could
potenti
target
therapeut
intervent
howev
accomplish
task
practic
obviou
deplet
pdc
use
exampl
cytotox
antibodi
toxinconjug
antibodi
could
possibl
sle
psoriasi
cancer
realist
approach
would
target
receptor
molecul
tlr
ifn
involv
pdcmediat
patholog
tolerogen
function
pdc
could
har
treatment
autoimmun
prevent
graft
reject
altern
tolerogen
function
could
suppress
order
promot
immun
tumour
antigenspecif
immun
suppress
could
achiev
target
antigen
pdc
use
antigen
conjug
pdcspecif
antibodi
final
use
agonist
abil
pdc
produc
ifn
could
exploit
treatment
chronic
acut
viral
infect
previous
mention
pdc
abl
sens
viral
nucleic
acid
may
also
sens
self
nucleic
acid
injur
tissu
appear
crucial
kickstart
inflammatori
tissu
repair
respons
therefor
surpris
continu
sens
self
nucleic
acid
pdc
associ
excess
inflammatori
respons
develop
autoimmun
demonstr
sle
psoriasi
may
also
hold
true
autoimmun
diseas
inhibit
pdc
function
may
therefor
repres
promis
strategi
treat
autoimmun
diseas
potenti
strategi
includ
target
two
pdcspecif
receptor
shown
block
abil
pdc
produc
type
ifn
anoth
potenti
strategi
inhibit
receptor
exclus
use
pdc
produc
type
ifn
importantli
alreadi
mention
strategi
advantag
specif
block
pdcderiv
type
ifn
without
interf
product
ifn
cell
type
therebi
avoid
widespread
inhibit
antivir
respons
pdc
also
exploit
induc
protect
immun
exampl
tumour
nonactiv
pdc
activ
produc
high
level
type
ifn
overturn
pdcinduc
immunosuppress
potenti
pdc
activ
includ
synthet
oligodinucleotid
contain
cpg
motif
cpg
odn
trigger
synthet
nucleosid
analogu
imiquimod
trigger
mention
gt
similar
strategi
could
explor
treat
chronic
viral
infect
character
impair
ifn
product
pdc
although
activ
pdc
particular
andor
initi
strong
innat
immun
respons
chronic
activ
cell
ifn
produc
promot
autoimmun
diseas
sle
cutan
inflammatori
diseas
character
interfac
dermat
aspect
pdc
biolog
focu
clinic
studi
agonist
either
alreadi
approv
exampl
imiquimod
basal
cell
carcin
oma
develop
use
infecti
diseas
allergi
asthma
cancer
expect
particular
agonist
action
depend
pdc
activ
addit
antagonist
recent
enter
clinic
trial
aim
reduc
chronic
ifn
product
pdc
approach
give
advantag
block
pdcmediat
product
ifn
larg
depend
without
affect
product
ifn
nontlrmedi
pathway
clinic
studi
progress
expect
learn
role
pdc
human
diseas
whether
cell
inde
good
target
therapeut
intervent
